[HTML][HTML] Lung cancer in never smokers–a review
An estimated 10–25% of lung cancers worldwide occur in never smokers, ie individuals
having smoked less than 100 cigarettes in their lifetime. Lung cancer in never smokers (LCINS) …
having smoked less than 100 cigarettes in their lifetime. Lung cancer in never smokers (LCINS) …
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International …
…, C Clary, AJ Torres, J Dahabreh, PJ Souquet… - The lancet …, 2006 - thelancet.com
Background Whether adjuvant chemotherapy improves survival of patients with non-small-cell
lung cancer (NSCLC) is not known. We aimed to compare the effect of adjuvant …
lung cancer (NSCLC) is not known. We aimed to compare the effect of adjuvant …
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international …
…, H Sakai, A Lingua, P Salman, PJ Souquet… - The Lancet …, 2021 - thelancet.com
Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
…, SG Nair, G Zalcman, J Wolf, PJ Souquet… - The lancet …, 2015 - thelancet.com
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
…, H Lena, D Moro-Sibilot, G Robinet, PJ Souquet… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
[HTML][HTML] From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French …
…, O Molinier, E Quoix, MP Revel, B Stach, PJ Souquet… - Annals of oncology, 2013 - Elsevier
Background Despite advances in cancer therapy, mortality is still high except in early-stage
tumors, and screening remains a challenge. The randomized National Lung Screening Trial (…
tumors, and screening remains a challenge. The randomized National Lung Screening Trial (…
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
D Planchard, B Besse, HJM Groen, PJ Souquet… - The Lancet …, 2016 - thelancet.com
Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
…, CFN Gorini, J Kultan, V Kolek, PJ Souquet… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide)
showed a significant improvement in overall survival versus platinum–…
showed a significant improvement in overall survival versus platinum–…
[HTML][HTML] Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …
Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non–small-cell lung cancer: Groupe …
P Fournel, G Robinet, P Thomas, PJ Souquet… - Journal of clinical …, 2005 - ascopubs.org
Purpose We conducted a phase III study to compare the survival impact of concurrent versus
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …